Shionogi & Co., Ltd. · TSE:4507

Shionogi & — Shareholder Meeting (June 2020)

26 slides from Shionogi &'s shareholder meeting presentation, June 2020

  1. Slide 1: The 155th Business Report

    The 155 Business Report th from April 1, 2019 to March 31, 2020.

  2. Slide 2: Current State of the Shionogi Group

    Current State of the Shionogi Group 2

  3. Slide 3: Shionogi Growth Strategy 2020 (SGS2020)

    Medium-Term Business Plan - Shionogi Growth Strategy 2020(SGS2020) - Medium-Term Business Plan Shionogi Growth Strategy 2020 (SGS2020) Start in April, 2014 → Update in 2016 3

  4. Slide 4: Steady progress of SGS2020

    Steady progress of SGS2020 Main KPIs in SGS2020 were achieved ahead of schedule (except for sales of new products and CCC) JGAAP FY2020 Target FY2019 KPI (Update ‘16-) results Sales of new products*1 200 B yen 62.9 B yen Growth Ordinary Income 150 B yen 151.8 B yen achieved ROIC*2 Over 13.5% 13.8% a

  5. Slide 5: Business Operations and Results

    Business Operations and Results 5

  6. Slide 6: Our Efforts to Fight COVID-19

    Our Efforts to Fight COVID-19 Supply chain • No impact on procurement of raw ingredients etc., production, or inventory – no hindrance to stable supply Promotion • Responded to needs of physicians and medical institutions, utilization of e-detail • Possible impact on influenza family sales due to co

  7. Slide 7: Highlight (1) Net Sales

    Highlight (1) Net Sales Net Sales Breakdown (B yen) Net Sales (FY2019) △7.9% (vs prior FY) FY2019 FY2018 (B yen) 108.6 Prescription drugs 128.7 344.7 363.7 335.0 Overseas subsidiaries 30.8 29.4 /export Contract manufacturin g 17.6 14.8 OTC and quasi- 10.3 8.1 drug Royalty FY2017 FY2018 FY2019 income

  8. Slide 8: Highlight (2) Profit Measures

    Highlight (2) Profit Measures Operating Ordinary Profit attributable income income to owners of parent △9.6% (vs prior FY) △8.9% (vs prior FY) △8.6% (vs prior FY) (B yen) (B yen) (B yen) 132.8 138.5 125.2 166.6 151.8 121.3 115.2 138.7 108.9 FY2017 FY2018 FY2019 FY2017 FY2018 FY2019 FY2017 FY2018 FY2

  9. Slide 9: Highlight (3) Summary of Consolidated Balance Sheets

    Highlight (3) Summary of Consolidated Balance Sheets (B yen) Total Total liabilities Total assets Liabilities and net assets △0.7% (vs prior FY) △15.3% (vs prior FY) +1.7% (vs prior FY) 778.7 773.7 106.3 90.0 672.4 683.6 FY2018 FY2019 FY2018 FY2019 FY2018 FY2019 JGAAP 9

  10. Slide 10: Key Results in FY2019

    Key Results in FY2019 Key Results in FY2019 1. Royalties and milestone payments, plus dividend income from ViiV 2. Research and development  Progress of growth drivers toward sustainable growth 3. Domestic/overseas business 4. Business innovation  Deliver new value and strengthen our business foun

  11. Slide 11: Royalties and Milestone Payments, Plus Dividend Income From ViiV

    ① Royalties and Milestone Payments, Plus Dividend Income From ViiV Royalties and milestone payments, plus dividend income stably increased 208.6 B yen 191.9 B yen △8.0% (vs prior FY) (B yen) ■ Royalty income from others ■ Milestone income from Roche ■ Royalty income and dividend income from ViiV ■ R

  12. Slide 12: Research and Development: High Priority Projects

    ② Research and Development: 8 High Priority Projects Psycho-neurological Cancer diseases Paradigm shift of Improve a wide range Regulatory cancer treatment with of psycho-neurological T cell synergy with existing diseases, such as inhibitor products addictions, with a new S-005151 mechanism of actio

  13. Slide 13: Research and Development: Progress of Growth Drivers

    ② Research and Development :Progress of Growth Drivers S-812217(zuranolone) Japan: initiation of Phase 2 study Depression U.S.: Phase Ⅲ study on (Sage) ①global:initiation of Phase 2 study S-600918 ①Refractory chronic cough, ②Japan: initiation of Phase 2 study ③Japan: ②Sleep Apnea Syndrome, ③Neuropat

  14. Slide 14: Our Efforts to Fight COVID-19

    Our Efforts to Fight COVID-19 Treatment: Discovery of Novel Therapeutic Drugs • Promising lead compounds have been selected in in vitro studies • Accelerating research activities with the goal of initiating clinical trials in FY2020 after confirming safetyof the compaounds Prevention: Discovery of P

  15. Slide 15: Domestic Business: Domestic Sales of Prescription Drugs

    ③ Domestic Business: Domestic Sales of Prescription Drugs Sales increased excluding sales of Flu-F (+18.0% vs prior FY) Sales of new products* (△25.8% vs prior FY) 73.8 54.7 (B yen)  Main reason of decrease of Influenza family sales of Xofluza®( △98.4% (vs (Xofluza® ,Rapiacta® prior FY) ) , Brightp

  16. Slide 16: Overseas Business

    ③ Overseas Business Maximize product value through combination of our own promotion and collaboration with business partners U.S. EU • Symproic(naldemedine) : • Rizmoic® (naldemedine) :  Termination of the alliance with Purdue and Marketing  Marketing agreement agreement with BDSI with Sandoz, Mol

  17. Slide 17: Business innovation: Building Innovation Platforms

    ④ Business innovation Building Innovation Platforms 1. Establishment of Stream I  Therapeutic/diagnostic  Digital platform drugs for influenza  Development capabilities, sales network 2. Signing of the Basic Agreement with Ping An Insurance  capability to create best-in-class innovative  Health

  18. Slide 18: Business innovation: Entry into Vaccine business

    ④ Business innovation Entry into Vaccine business 3. Expand business in the preventive field by making UMN Pharma a wholly owned subsidiary • Acquiring UMN’s original vaccine technology • Promote to develop preventive vaccines against COVID-19, influenza infections, etc. Characteristics of platform

  19. Slide 19: Shareholder Return Policy Through Which Shareholders Can Feel Our Growth

    Shareholder Return Policy Through Which Shareholders Can Feel Our Growth Plan to increase dividend for Planning to increase 8 consecutive years dividend for 8 consecutive years 103 (yen) 106 120 (Planned)(Planned) 94 100 82 80 72 53 62 (Planned) 60 46 52 50 42 44 34 38 40 28 20 22 24 20 0 FY 2012 20

  20. Slide 20: Challenges Ahead

    Challenges Ahead @ SHIONOGI 20

  21. Slide 21: Background to the formulation of the new medium-term plan

    Background to the formulation of the new medium-term management plan SGS2020 <Achievements> <Issues>  Achievement of main KPIs  Growth of new products  Continuous creation of in-house products  Growth of overseas businesses  Strengthening of business operations  Per-employee productivity* etc.

  22. Slide 22: Vision 2030: Building Innovation Platforms to Shape the Future of Healthcare

    2030 Vision - What we want to achieve by 2030 - Vision 2030 Building Innovation Platforms to Shape the Future of Healthcare 22

  23. Slide 23: Strategy to Achieve 2030 Vision: STS2030

    Strategy to Achieve 2030 Vision Strategy to achieve 2030 Vision STS2030 - Shionogi Transformation Strategy 2030 - New growth achieved through business transformation STS2030 STS Phase1 (’20 -’24) STS Phase2 (’25 -) ⇒ New medium-term business plan ⇒ Next medium-term business plan Realizing our transf

  24. Slide 24: KPIs in the New Medium-Term Plan

    8 KPIs in the New Medium-Term Plan FY2019 FY2024 FY2019 IFRS IFRS JGAAP Revenue 333.4 B yen 500.0 B yen 335.0 B yen Core operating profit* 127.4 B yen 150.0 B yen - Core operating profit margin 38.2% Over 30% - Overseas sales ratio 18.5% Over 50% 18.2% (excl. RYT) Original pipeline ratio 67% Over 60

  25. Slide 25: Shionogi's Philosophy

    Shionogi’s Philosophy Supply the best possible medicine to protect the health and well-being of the patients we serve 25

  26. Slide 26: Forward-Looking Statements

    Forward-Looking Statements  Forecast or target figures in this material are neither official forecasts of earnings and dividends nor guarantee of target, achievement and forecasts, but present the midterm strategies, goals and visions. Official earnings guidance should be referred to in the disclos

Shionogi & — Shareholder Meeting (June 2020) on 6ix